<DOC>
	<DOCNO>NCT00006137</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine sensitive outcome measure ( functional morphological ) progressive renal injury patient IgA nephropathy . II . Determine patient destine progress injury order target therapy . III . Elucidate determinant progression patient exhibit evidence either increase impairment ultrafiltration capacity ongoing destruction nephron .</brief_summary>
	<brief_title>Pilot Study Enalapril Renal Function Patients With IgA Nephropathy</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive oral enalapril daily . Treatment continue 5 year absence unacceptable toxicity . Patients undergo renal function study every 6-12 month 5 year . Patients undergo renal biopsy 36-48 month study entry .</detailed_description>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>Histologically confirm IgA nephropathy , diagnose within past 3 year Clinical presentation either isolate hematuria/proteinuria le 3 year OR Acute nephritic nephrotic syndrome No secondary form IgA nephropathy associate chronic inflammatory disease bowel liver No end stage renal failure define follow : Glomerular filtration rate le 15 mL/min AND Extensive glomerulosclerosis tubulointerstitial damage No systemic lupus erythematosus systemic ( extrarenal ) vasculitis ( HenochSchonlein syndrome ) Healthy volunteer accrue control group No concurrent medical psychiatric illness would preclude study</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>IgA glomerulonephritis</keyword>
	<keyword>rare disease</keyword>
	<keyword>renal genitourinary disorder</keyword>
</DOC>